Literature DB >> 25341070

Continuous monitoring of arthritis in animal models using optical imaging modalities.

Taeyoon Son1, Hyung-Ju Yoon2, Saseong Lee2, Won Seuk Jang3, Byungjo Jung1, Wan-Uk Kim4.   

Abstract

Given the several difficulties associated with histology, including difficulty in continuous monitoring, this study aimed to investigate the feasibility of optical imaging modalities—cross-polarization color (CPC) imaging, erythema index (EI) imaging, and laser speckle contrast (LSC) imaging—for continuous evaluation and monitoring of arthritis in animal models. C57BL/6 mice, used for the evaluation of arthritis, were divided into three groups: arthritic mice group (AMG), positive control mice group (PCMG), and negative control mice group (NCMG). Complete Freund’s adjuvant, mineral oil, and saline were injected into the footpad for AMG, PCMG, and NCMG, respectively. LSC and CPC images were acquired from 0 through 144 h after injection for all groups. EI images were calculated from CPC images. Variations in feet area, EI, and speckle index for each mice group over time were calculated for quantitative evaluation of arthritis. Histological examinations were performed, and the results were found to be consistent with those from optical imaging analysis. Thus, optical imaging modalities may be successfully applied for continuous evaluation and monitoring of arthritis in animal models.

Entities:  

Mesh:

Year:  2014        PMID: 25341070     DOI: 10.1117/1.JBO.19.10.106010

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  2 in total

Review 1.  Model answers: Rational application of murine models in arthritis research.

Authors:  Robert A Benson; Iain B McInnes; Paul Garside; James M Brewer
Journal:  Eur J Immunol       Date:  2017-12-14       Impact factor: 5.532

Review 2.  Clinical applications of laser speckle contrast imaging: a review.

Authors:  Wido Heeman; Wiendelt Steenbergen; Gooitzen van Dam; E Christiaan Boerma
Journal:  J Biomed Opt       Date:  2019-08       Impact factor: 3.758

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.